Jaka jest cena za EFFECTOR Therapeutics, Inc. (EFTRW)

Cena za EFFECTOR Therapeutics, Inc. (EFTRW) wynosi $0.0006

Jaka jest kapitalizacja rynkowa dla EFFECTOR Therapeutics, Inc. (EFTRW)

Kapitalizacja rynkowa dla EFFECTOR Therapeutics, Inc. (EFTRW) wynosi $2.82K

EFFECTOR Therapeutics, Inc. (EFTRW) EPS

eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.

Rok	EPS	Zmień
Za mało danych dla podanych dat.

Rok

EPS

Zmień

Za mało danych dla podanych dat.

Firma	EPS	Różnica w EPS	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$13.70	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Firma

EPS

Różnica w EPS

Kraj